BVF Inc. IL Raises Holdings in TScan Therapeutics, Inc. $TCRX

Key Points

• BVF Inc. IL increased its stake in TScan Therapeutics by 63.6%, acquiring an additional 1,900,000 shares, bringing their total ownership to 4,889,474 shares valued at $6,747,000.
• Major hedge funds including Wells Fargo and Wellington Management have also increased their investments in TScan Therapeutics, indicating strong institutional support with 82.83% of shares held by institutional investors.
• TScan Therapeutics recently reported earnings of ($0.28) per share, meeting analyst expectations while generating revenue of $3.08 million, significantly above the consensus estimate of $1.31 million.

BVF Inc. IL boosted its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 63.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,889,474 shares of the company's stock after purchasing an additional 1,900,000 shares during the quarter. BVF Inc. IL owned about 8.64% of TScan Therapeutics worth $6,747,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Troluce Capital Advisors LLC lifted its position in TScan Therapeutics by 58.3% in the first quarter. Troluce Capital Advisors LLC now owns 83,758 shares of the company's stock worth $116,000 after purchasing an additional 30,844 shares during the period. Hsbc Holdings PLC acquired a new position in shares of TScan Therapeutics during the 1st quarter worth about $49,000. Aberdeen Group plc grew its position in shares of TScan Therapeutics by 0.9% during the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after buying an additional 7,744 shares during the period. Nuveen LLC acquired a new position in shares of TScan Therapeutics in the 1st quarter valued at approximately $97,000. Finally, Deutsche Bank AG grew its position in shares of TScan Therapeutics by 149.4% in the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company's stock valued at $73,000 after purchasing an additional 31,481 shares during the period. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Trading Down 2.6%

TCRX stock traded down $0.05 during mid-day trading on Monday, reaching $1.86. The company's stock had a trading volume of 70,845 shares, compared to its average volume of 446,563. The company has a market cap of $105.56 million, a price-to-earnings ratio of -1.71 and a beta of 1.00. The business's 50 day moving average price is $1.76 and its 200 day moving average price is $1.61. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. TScan Therapeutics, Inc. has a 12 month low of $1.02 and a 12 month high of $6.23.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). The firm had revenue of $3.08 million during the quarter, compared to analysts' expectations of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. On average, equities research analysts predict that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on TCRX. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $7.80.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.